Carregant...
Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital
BACKGROUND: Sorafenib is first line chemotherapy for advanced hepatocellular carcinoma (HCC). There are little real-world experiences with sorafenib done on US population except for the US arm of the GIDEON study, a phase IV multi-national study. In this context, we present a single institution expe...
Guardat en:
| Publicat a: | J Gastrointest Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6219969/ https://ncbi.nlm.nih.gov/pubmed/30505582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.06.09 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|